Cargando…
Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743765/ https://www.ncbi.nlm.nih.gov/pubmed/36510220 http://dx.doi.org/10.1186/s13063-022-06972-9 |
| _version_ | 1784848793700663296 |
|---|---|
| author | Hill, Nathan R. Lasserson, Daniel Thompson, Ben Perera-Salazar, Rafael Wolstenholme, Jane Bower, Peter Blakeman, Thomas Fitzmaurice, David Little, Paul Feder, Gene Qureshi, Nadeem Taal, Maarten Townend, Jonathan Ferro, Charles McManus, Richard Hobbs, F. D. Richard |
| author_facet | Hill, Nathan R. Lasserson, Daniel Thompson, Ben Perera-Salazar, Rafael Wolstenholme, Jane Bower, Peter Blakeman, Thomas Fitzmaurice, David Little, Paul Feder, Gene Qureshi, Nadeem Taal, Maarten Townend, Jonathan Ferro, Charles McManus, Richard Hobbs, F. D. Richard |
| author_sort | Hill, Nathan R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9743765 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97437652022-12-13 Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial Hill, Nathan R. Lasserson, Daniel Thompson, Ben Perera-Salazar, Rafael Wolstenholme, Jane Bower, Peter Blakeman, Thomas Fitzmaurice, David Little, Paul Feder, Gene Qureshi, Nadeem Taal, Maarten Townend, Jonathan Ferro, Charles McManus, Richard Hobbs, F. D. Richard Trials Correction BioMed Central 2022-12-12 /pmc/articles/PMC9743765/ /pubmed/36510220 http://dx.doi.org/10.1186/s13063-022-06972-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Hill, Nathan R. Lasserson, Daniel Thompson, Ben Perera-Salazar, Rafael Wolstenholme, Jane Bower, Peter Blakeman, Thomas Fitzmaurice, David Little, Paul Feder, Gene Qureshi, Nadeem Taal, Maarten Townend, Jonathan Ferro, Charles McManus, Richard Hobbs, F. D. Richard Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title_full | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title_fullStr | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title_full_unstemmed | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title_short | Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| title_sort | correction: benefits of aldosterone receptor antagonism in chronic kidney disease (barack d) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743765/ https://www.ncbi.nlm.nih.gov/pubmed/36510220 http://dx.doi.org/10.1186/s13063-022-06972-9 |
| work_keys_str_mv | AT hillnathanr correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT lassersondaniel correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT thompsonben correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT pererasalazarrafael correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT wolstenholmejane correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT bowerpeter correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT blakemanthomas correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT fitzmauricedavid correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT littlepaul correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT federgene correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT qureshinadeem correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT taalmaarten correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT townendjonathan correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT ferrocharles correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT mcmanusrichard correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda AT hobbsfdrichard correctionbenefitsofaldosteronereceptorantagonisminchronickidneydiseasebarackdtrialamulticentreprospectiverandomisedopenblindedendpoint36monthstudyof2616patientswithinprimarycarewithstage3bchronickidneydiseasetocomparetheefficacyofspironolactone25mgonceda |